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Defects in axonal transport are thought to contribute to the pathogenesis of neurodegenerative disease.
Because a-tubulin acetylation facilitates axonal transport, inhibition of the a-tubulin deacetylating enzymes,
histone deacetylase 6 (Hdac6) and silent information regulator 2 (Sirt2), is thought to be an interesting thera-
peutic strategy for these conditions. Amyotrophic lateral sclerosis (ALS) is a one such rapidly progressive
and fatal neurodegenerative disorder, in which axonal transport defects have been found in vitro and in
vivo. To establish whether the inhibition of Hdac6 or Sirt2 may be of interest for ALS treatment, we investi-
gated whether deleting Hdac6 or Sirt2 from the superoxide dismutase 1, SOD1G93A mouse affects the motor
neuron degeneration in this ALS model. Deletion of Hdac6 significantly extended the survival of SOD1G93A
mice without affecting disease onset, and maintained motor axon integrity. This protective effect was asso-
ciated with increased a-tubulin acetylation. Deletion of Sirt2 failed to affect the disease course, but also did
not modify a-tubulin acetylation. These findings show that Hdac6, rather than Sirt2, is a therapeutic target for
the treatment of ALS. Moreover, Sirt2 appears not to be a major a-tubulin deacetylase in the nervous system.
INTRODUCTION
Axonal transport defects are thought to contribute to the patho-
genesis of neurodegenerative disorders and restoring transport
is suggested to be a therapeutic strategy. Post-translational
modification of microtubules is a major regulator of axonal
transport. One such modification, acetylation of a-tubulin,
has been studied intensively in neurodegeneration. It promotes
axonal transport by recruiting the molecular motor proteins
kinesin-1 and cytoplasmic dynein to microtubules (1,2).
Decreased acetylation of a-tubulin underlies the transport
defects in Huntington’s disease (HD) and Charcot–Marie–
Tooth disease (CMT) (1,3). Moreover, neuroprotective
effects of genetic or pharmacological inhibition of Hdac6 and
Sirt2, the two major a-tubulin deacetylases, have been reported
in models of HD, CMT and Parkinson’s disease (PD) (1,3–6).
However, these enzymes have several other functions in the
cell. For instance, Sirt2 has recently been suggested to play a
role in programmed necrosis (7). In particular however, Hdac6
plays a major role in the degradation of misfolded proteins
that play a causal role in the mechanism of neurodegeneration.
It can bind ubiquitinated proteins and dynactin simultaneously
(8). It thus enhances transport of ubiquitinated proteins by
the cytoplasmic dynein motor to the microtubule-organizing
center where these are degraded through the autophagymachin-
ery (9). This ubiquitin-dependent function of Hdac6 is depend-
ent upon the a-tubulin deacetylase activity of this enzyme (8,9).
Thus, deacetylase inhibition may have deleterious effects as
well. It is therefore necessary to evaluate the net effect of the
inhibition of these multifunctional enzymes before accepting
them as favorable therapeutic targets.
Amyotrophic lateral sclerosis (ALS) is a progressive, incur-
able and fatal condition characterized by the loss of upper and
lower motor neurons. Its molecular pathogenesis is multifac-
torial and modified by non-neuronal cells (10,11). In animal
models of ALS, axonal transport defects are present early in
life, well before the onset of clinical deficits (12,13). The rele-
vance of axonal transport dysfunction for human ALS is
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demonstrated by the occurrence of spheroids, axonal swellings
packed with filamentous material, in familial and sporadic
ALS (14,15). In order to elucidate whether deacetylase inhibi-
tors may be a promising avenue for intervention in ALS, we
investigated the effect of Hdac6 and Sirt2 deletion on the
motor neuron degeneration in the superoxide dismutase 1,
SOD1G93A, mouse model of ALS.
RESULTS
Hdac6 or Sirt2 knockout does not affect neuromuscular
function in mice
In this study, we have used Sirt2 knockout (KO) mice,
obtained by mating conditional Sirt2 KO mice (16) with
CMV-Cre mice, and Hdac6 KO mice (17). We confirmed
the absence of Hdac6 and Sirt2 protein from nervous tissues
of Hdac6 KO and Sirt2 KO mice, respectively (Fig. 1A and
B). In wild-type mice, mainly the smaller 39 kDa isoform
of Sirt2 was expressed as reported before (18). Analysis of
Sirt2 mRNA expression levels revealed a complete loss
of Sirt2 in homozygous Sirt2 KO mice (Sirt22/2) and a
50% decrease in heterozygous Sirt2 KO mice (Sirt2+/2)
compared with control littermates (Sirt2+/+) (Fig. 1C). As
a result of the location of the Hdac6 gene on the
X-chromosome, there is variable protein expression in hetero-
zygous females as a result of lionization, and male mice—who
share only one X-chromosome—are either non-transgenic
or full KO. Therefore, no heterozygous Hdac6 KO mice
were used in this study.
We first excluded that the deletion of either Hdac6 or Sirt2
results in a neuromuscular phenotype on itself. Motor perform-
ance was evaluated using an accelerating rotarod and was not
different between Hdac6 KO mice and control mice (Supple-
mentary Material, Fig. S1A) or between Sirt2 KO and control
mice (Supplementary Material, Fig. S1B). The compound
muscle action potential (CMAP), an electrophysiological
measure of neuromuscular innervation, of Hdac6 KO and
Sirt2KOmice was not different from control mice (Supplemen-
taryMaterial, Fig. S1C andD). To excludemore subtle changes,
we quantified the number of neurons in the ventral horn
of lumbar spinal cord as well as the fraction of innervated neuro-
muscular junctions (NMJs) in the gastrocnemius muscle. No
differences in these parameters were detected (Supplementary
Material, Fig. S2).
Effect of deletion of Hdac6 on the course of motor neuron
degeneration in SOD1G93A mice
Hdac6 KO mice were crossbred with SOD1G93A mice. As
disease onset and survival of SOD1G93A mice vary between
litters and genders (19) and female Hdac62/2 mice do not
have female control littermates within the same litter, only
male mice were included in this study. Age at disease onset,
defined by failure on the paw grip endurance (PaGE) test,
was not affected by the absence of Hdac6: it was 132+ 2
days for SOD1G93A/Hdac6Y/+ (n ¼ 25) and 135+ 2 days for
SOD1G93A/Hdac6Y/2 (n ¼ 26) mice (P ¼ 0.236) (Fig. 2A). In
contrast, deletion of Hdac6 significantly prolonged survival
of SOD1G93A mice from 150+ 2 days for SOD1G93A/
Figure 1. Expression of Sirt2 and Hdac6 in nervous tissue of KO mice. (A) Hdac6 protein expression in 90-day-old Hdac6 KO mice. Glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh) was used as a loading control. (B) Sirt2 protein expression in 180-day-old Sirt2 KO mice. Arrows indicate 39 kDa and 43 kDa
isoforms of Sirt2 and asterisks indicate a non-specific band. b-Actin was used as a loading control. (C) Different panels show Sirt2 mRNA expression levels in
various tissues of 80-day-old Sirt2 KO mice. Values are normalized to the average of five mRNA controls [DNA-directed RNA polymerase II A (Polr2a), hypo-
xanthine phosphoribosyltransferase 1(Hprt1), ribosomal protein, large, P0 (Rplp0), Gapdh and b-actin] and represented as the percentage of mean+SEM (n ¼
5–6). The signal for Sirt2 mRNA in Sirt22/2 mice was below detection limits. Student’s t-test, ∗∗∗P, 1 × 1025.
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Hdac6Y/+ mice (n ¼ 28) to 160+ 3 days for SOD1G93A/
Hdac6Y/2 mice (n ¼ 29) (P ¼ 0.008) (Fig. 2B). Median sur-
vival was increased from 145 days for SOD1G93A/Hdac6Y/+
mice to 159 days for Hdac6-deficient SOD1G93A mice. This
effect may appear modest, but it should be noted that survival
after disease onset was increased with 60% from 15.7+ 1.1
days for SOD1G93A/Hdac6Y/+ to 25.1+ 2.7 days for
SOD1G93A/Hdac6Y/2 mice (P ¼ 0.003) (Fig. 2C).
To confirm the survival benefit observed, we studied the
CMAP in age-matched (130 days of age), symptomatic litter-
mates, and quantified the innervation of their NMJs as well as
the remaining neurons in the ventral spinal cord. CMAP
amplitudes in SOD1G93A/Hdac6Y/2 mice were significantly
higher compared with control SOD1G93A/Hdac6Y/+ mice
(Fig. 2D, P ¼ 0.017). Consistent with this increased function,
NMJ innervation of the gastrocnemius muscle was better pre-
served in SOD1G93A/Hdac6Y/2 mice (47% complete innerv-
ation) compared with controls (32% complete innervation)
[Fig. 2E, odds ratio (OR) ¼ 0.535 (0.429–0.667), P , 0.001],
and the number of remaining neurons in the ventral horn of
SOD1G93A/Hdac6Y/2 mice was significantly higher than in
SOD1G93A/Hdac6Y/+mice (Fig. 2F, P ¼ 0.006). This protective
effect tended to be more pronounced for large neurons
(.400 mm2: +60%; 250–400 mm2: +50%) than small
neurons (200–250 mm2: +38%; 150–200 mm2: +18%).
The beneficial effects observed in the SOD1G93A/Hdac6Y/2
mice were associated with significantly increased levels of
a-tubulin acetylation in the spinal cord (P ¼ 0.035), sciatic
nerve (P ¼ 0.021) and brain (P ¼ 0.005) (Fig. 3 and Supple-
mentary Material, Fig. S3). The expression of the SOD1G93A
transgene was not affected by the deletion of Hdac6 and
thus cannot account for the increase in survival of
SOD1G93A/Hdac6Y/2 mice (Fig. 3A and Supplementary Mater-
ial, Fig. S3A).
These results indicate that Hdac6 is a major a-tubulin dea-
cetylase in the nervous system and that absence of Hdac6 does
not induce neuromuscular abnormalities. Deletion of Hdac6
from the SOD1G93A mouse significantly slowed the progres-
sion of motor neuron degeneration, suggesting that in this
condition the beneficial effects of the absence of this
enzyme (e.g. on axonal transport) outweigh its hazardous
effects (e.g. on autophagy).
Figure 2. Effect of deletion of Hdac6 on the course of motor neuron degeneration in SOD1G93A mice. (A) Probability of disease onset assessed by failure on the
PaGE test (SOD1G93A/Hdac6Y/+ n ¼ 25, black; SOD1G93A/Hdac6Y/2 n ¼ 26, grey; log-rank, P ¼ 0.236). (B) Probability of survival (SOD1G93A/Hdac6Y/+ n ¼
28, black; SOD1G93A/Hdac6Y/2 n ¼ 29, grey; log-rank, P ¼ 0.008). (C) Survival after disease onset (SOD1G93A/Hdac6Y/+ n ¼ 25; SOD1G93A/Hdac6Y/2 n ¼ 26;
Student’s t-test, P ¼ 0.003). (D) CMAP amplitude of 130-day-old mice (SOD1G93A/Hdac6Y/+ n ¼ 7; SOD1G93A/Hdac6Y/2 n ¼ 5; Student’s t–test, ∗P , 0.05).
(E) Proportion of complete (full innervation; black) and incomplete (partial or no innervation; grey) innervated NMJs in gastrocnemius muscle at 130 days of age
[n ¼ 4 per genotype; Chi-square test, OR ¼ 0.535 (0.429–0.667), ∗P, 0.001]. (F) Quantification of neurons in the ventral horn of 130-day-old Hdac6+/+
(black) and Hdac62/2 (grey) mutant SOD1G93A mice categorized per size and normalized to 300 000 mm2 of ventral horn (n ¼ 5 per genotype; univariate
ANOVA, P ¼ 0.006 for genotype). (C, D and F) Data are represented as mean+SEM.
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Effect of deletion of Sirt2 on the course of motor neuron
degeneration in SOD1G93A mice
To study the effect of Sirt2 deletion, we crossed SOD1G93A
mice with Sirt2 KO mice. In contrast to what was observed
for Hdac6, Sirt2 deletion did not affect disease onset or survival
of SOD1G93A mice (Fig. 4A and B). In line with this lack of
effect on behavioral disease parameters, we did not find any dif-
ference in CMAP amplitude or number of remaining neurons in
the ventral spinal cord of symptomatic SOD1G93A/Sirt2+/+
mice and SOD1G93A mice deficient for Sirt2 (Fig. 4C and D).
Reduction of Sirt2 did not change SOD1G93A expression
(Fig. 3A and Supplementary Material, Fig. S3A).
To further explore the discrepancy between the effects of
Hdac6 KO versus Sirt2 KO, we studied the effect of Sirt2 de-
letion on the acetylation of a-tubulin in end-stage SOD1G93A
mice. In contrast to what we found in Hdac6-deficient mice,
we did not find any difference in the level of acetylated
a-tubulin upon deletion of Sirt2 (Fig. 3 and Supplementary
Material, Fig. S3). We confirmed this lack of effect at an
earlier disease stage in age-matched (160 days of age) symp-
tomatic littermates (Supplementary Material, Fig. S4). To
exclude a confounding effect of the presence of SOD1G93A
and to elucidate whether Sirt2 actually regulates a-tubulin
acetylation in the nervous system at all, we analyzed
a-tubulin acetylation in spinal cord, brain and sciatic nerve
of Sirt2 KO mice. Surprisingly, but consistent with the
results obtained, no differences in a-tubulin acetylation were
present (Supplementary Material, Fig. S5). To exclude that
the absence of Sirt2 was compensated for by upregulation of
Hdac6, we quantified Hdac6 expression in 80-day-old and
250-day-old Sirt2 KO mice, but found no alteration of
Hdac6 mRNA in spinal cord and brain (Supplementary Mater-
ial, Fig. S6).
These data suggest that although Sirt2 is clearly expressed in
the nervous system (Fig. 1A), its contribution to the regulation
of a-tubulin acetylation in this tissue is minor. Deletion of Sirt2
does not induce neuromuscular abnormalities on itself and also
fails to modify the disease course in the SOD1G93A mouse.
DISCUSSION
Inhibitors of Hdac6 and Sirt2 have been suggested to be poten-
tial treatments for neurodegenerative diseases as they increase
Figure 3. Analysis of a-tubulin acetylation in end-stage SOD1G93A mice deficient for Hdac6 or Sirt2. (A) Representative western blots of acetylated and total
a-tubulin levels in the nervous system. (B) Quantification of western blots. Levels of acetylated a-tubulin over total a-tubulin were normalized to Gapdh and
shown as mean+SEM. SOD1G93A/Hdac6 KO n ¼ 4–5 per tissue and genotype; Student’s t-test, ∗P, 0.05. SOD1G93A/Sirt2 KO n ¼ 2–4 per tissue and geno-
type; One-way ANOVA, spinal cord P ¼ 0.954, sciatic nerve P ¼ 0.821.
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the acetylation of lysine at position 40 of a-tubulin. Increased
acetylation at this site promotes the recruitment of the molecu-
lar motors kinesin-1 and cytoplasmic dynein (1,2), and
facilitates intracellular trafficking and axonal transport.
Defects in axonal transport have been implicated in the patho-
genesis of neurodegenerative disorders characterized by
the accumulation of misfolded protein [reviewed in (20)].
Protein accumulations can arise from deregulated transport,
and in turn block the transport of other proteins, organelles
and vesicles. Hence, improving axonal transport by inhibiting
a-tubulin deacetylation is thought to be a strategy to treat
these diseases. Genetic and pharmacological inhibitions of
Hdac6 and Sirt2 have been studied in a variety of neurodegen-
erative disorders, such as HD, PD, Alzheimer’s disease (AD),
spinal and bulbar muscular atrophy (SBMA) and CMT
(1,3,21–23), but these studies have generated contradictory
results. In models of AD and SBMA, Hdac6 activation
rather than inhibition was beneficial, (22,23). In contrast, in
a model of HD, Hdac6 inhibition rescued the impaired trans-
port of the brain-derived neurotrophic factor (BDNF) in striat-
al neurons in vitro (1). However, in an in vivo mouse model of
HD, genetic deletion of Hdac6 failed to modify disease pro-
gression or BDNF transport (24). In a CMT mouse model,
Hdac6 inhibition reversed the phenotype in vivo and rescued
the axonal transport defects (3). In cellular and Drosophila
models of PD and HD, inhibition of Sirt2 was reported to
have neuroprotective effects (4–6). These variable results
may be explained by the fact that these enzymes have
several different functions and several different substrates in
the cell. This is particularly true for Hdac6, which plays an im-
portant role in autophagy through its ubiquitin-binding ability
(8,9). The involvement of this enzyme in both axonal transport
and misfolded protein degradation argues for a dual role of this
protein in neurodegeneration. Depending on the type of neuro-
degeneration and perhaps even the disease stage, the import-
ance of enhanced autophagy may outweigh the importance
of restored axonal transport.
Ever since axonal swellings—resulting from neurofilament
accumulations— have been observed in familial and sporadic
ALS (14,15), defects in axonal transport are intensively
studied in ALS. In order to elucidate whether increasing
axonal transport through a-tubulin deacetylase inhibitors may
Figure 4. Effect of deletion of Sirt2 on the course of motor neuron degeneration in SOD1G93A mice. (A) Probability of disease onset in Sirt2+/+, Sirt2+/2 and
Sirt22/2 mutant SOD1G93A mice assessed by failure on the PaGE test (log-rank, P ¼ 0.376). (B) Probability of survival of double transgenic mice (log-rank, P ¼
0.870). (A, B) The numbers of SOD1G93A mice used were: Sirt2+/+ n ¼ 19, Sirt2+/2 n ¼ 16, Sirt22/2 n ¼ 12. (C) CMAP amplitude of 160-day-old SOD1G93A
mice (Sirt2+/+ n ¼ 7; Sirt2+/2 n ¼ 12, Sirt22/2 n ¼ 8; one-way ANOVA, P ¼ 0.737). (D) Quantification of neurons in the ventral horn of the lumbar spinal
cord categorized per size and normalized to 300 000 mm2 of ventral horn of Sirt2+/+, Sirt2+/2 and Sirt22/2 mutant SOD1G93A mice at 160 days of age (n ¼ 3–4
per genotype, univariate ANOVA, P ¼ 0.655 for genotype). (C, D) Data are represented as mean+SEM.
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be a promising avenue for intervention in this disease, we inves-
tigated the effect of Hdac6 and Sirt2 deletion on the motor
neuron degeneration in the SOD1G93A mouse model of ALS.
The absence of the Hdac6 protein did not result in a neuro-
muscular phenotype on behavioral and physiological levels.
This is consistent with previous findings of Bobrowska
et al., who tested motor coordination and balance, forelimb
grip strength and spontaneous motor activity of Hdac6 KO
mice, and found no difference with control mice (24). Interest-
ingly, no differences were observed in aggregate load of
mutant huntingtin, suggesting that the role of Hdac6 in hun-
tingtin aggregate clearance is minor or compensated by
another protein. Although genetic depletion of Hdac6 indeed
resulted in highly increased levels of acetylated a-tubulin,
this did not modify behavioral phenotypes in HD mice. In
contrast, we found that the absence of Hdac6 successfully
modified the disease course in the SOD1G93A mouse. Hdac6
deletion did not affect disease onset, but significantly extended
the survival after disease onset with as much as 60%. This in-
crease in survival after disease onset is relevant for translation
to human ALS, as treatment in patients is initiated after
disease onset only.
As deletion ofHdac6 from the SOD1G93Amouse significantly
slowed the progression of motor neuron degeneration, these
results suggest that in this condition the beneficial effects of
the absence of this enzyme (e.g. on axonal transport) are
greater than its hazardous effects (e.g. on autophagy). This is
in contrast to what has been described for models of HD, AD
and SBMA (22–24). The benefit of Hdac6 activation rather
than inhibition may point towards a more important role of
impaired autophagy in the pathological mechanism of these dis-
orders.Hdac6 inhibitionwas also beneficial in amodel formotor
neuropathy, most probably by increasing axonal transport
through increased levels of acetylated a-tubulin (3). It would
be interesting to verify whether the axonal transport in
SOD1G93Amice increases upon deletion ofHdac6. Unfortunate-
ly, measurement of axonal transport in adult mouse motor
neurons in vitro is not feasible, in contrast to what can be done
in sensory neurons (3), and techniques for measuring axonal
transport in vivo are still being developed (12).
The absence of the other tubulin deacetylating enzyme,
Sirt2, did not induce neuromuscular abnormalities, but did
not modify the motor neuron degeneration in the mutant
SOD1 mice either. Surprisingly, we found that although
Sirt2 is clearly expressed in the nervous system, its contribu-
tion to the regulation of a-tubulin acetylation in this tissue
is minor. These results were confirmed in the absence of
SOD1G93A in order to exclude a confounding effect of the
presence of SOD1G93A. This is in contrast to what is generally
accepted (25,26), but in agreement with the in vivo findings of
Bobrowska et al. (27). Obviously, our data do not exclude that
Sirt2 has a subtle effect on acetylation in certain cellular com-
partments that escape detection by western blot on the total
tissue lysate, e.g. the oligodendrocyte, in which Sirt2 is
highly expressed (28). But even then, our data show that dele-
tion of Sirt2 from those compartments does not affect motor
neuron degeneration in the SOD1G93A mouse, in spite of the
fact that oligodendrocytes have been shown to contribute to
neurodegeneration (29). Furthermore, as Sirt2 has been recent-
ly shown to play a pivotal role in programmed necrosis (7),
our data indicate that this type of cell death does not contribute
to the process of neurodegeneration such as seen in the
SOD1G93A model of ALS.
In conclusion, these findings suggest that inhibition of
Sirt2 does not provide beneficial effect on ALS in rodents in
vivo, in contrast to what has been reported in in vitro and Dros-
ophilamodels of PD (5) and HD (4,6). In contrast, Hdac6 inhib-
ition may be an appealing therapeutic strategy in ALS, as
deletion of Hdac6 attenuates motor neuron degeneration in the
SOD1G93A mouse. This attenuation is associated with an in-
crease of acetylated a-tubulin, suggesting that its protective
mechanism is related to changes in intracellular transport.
METHODS
Additional information is provided in Supplementary
Methods.
Transgenic mice
Sirt2 KO mice, obtained by mating conditional Sirt2 KO mice
(16) with CMV-Cre mice, and Hdac6 KO mice (17) were main-
tained in a C57Bl6/J background. Mice overexpressing human
SOD1G93A [B6SJL-TgN(SOD1-G93A)1Gur; The Jackson La-
boratory] were crossed into a C57Bl6 background for more
than 20generations.All animalswere housed under standard con-
ditions according to the guidelines of the University of Leuven.
Disease onset and survival
To determine disease onset in SOD1G93A mice, motor perform-
ance was evaluated twice every week by the PaGE test. For
this, mice were placed on a wire grid upside down until they
drop or reach the maximum of 60 s. Failure on the PaGE
test was designated by dropping of the mouse before 60 s.
Three SOD1G93A/Hdac6Y/+ mice and three SOD1G93A/
Hdac6Y/2 mice were excluded from this test based upon
poor initial performance, i.e. failure within the first 4 weeks
of scoring. Survival was determined by loss of the righting
reflex within 30 s. When this was the case, the mouse was
sacrificed and this time point (equal to end stage) was consid-
ered as the time of death. Both the disease onset and survival
are presented as Kaplan–Meier curves. For all the experi-
ments, the investigator was blinded for the genotype.
Nerve conduction study
Mice were anesthetized with isoflurane and placed on a
heating pad to maintain body temperature. Nerve conduction
was measured using sub-dermal needle electrodes (Tech-
nomed Europe) and a Medelec EMG monitor (Medelec
Vickers/Modul USA). To measure the compound muscle
action potential (CMAP), the stimulating electrode was
placed at the sciatic notch and the recording electrode at
the level of the gastrocnemius muscle.
Histological analyses
Mice were sacrificed using CO2 immediately followed by dis-
section of the gastrocnemius muscle, which was instantly
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frozen in isopentane cooled with liquid nitrogen. To determine
NMJ innervation, 40 mm thick longitudinal sections were
stained with Alexa 555 conjugated a-bungarotoxin (1/500;
Invitrogen) and rabbit anti-NF200 (1/200; Sigma) to visualize
the axon innervating the NMJ. More than 100 NMJs spread
over three to four sections of the gastrocnemius muscle were
scored per animal. After transcardiac perfusion with phosphate
buffered saline (PBS) and PBS with 4% paraformaldehyde
(PFA), the lumbar region of the spinal cord was dissected,
further fixed with 4% PFA, dehydrated in 30% sucrose solu-
tion and embedded in OCT medium (VWR). Sixty cryosec-
tions of 20 mm thickness each were made. Every sixth
cryosection was stained with cresyl violet (Sigma) and used
for quantitative analysis of the number of neurons. Thus, in
total 10 sections were analyzed per spinal cord covering a
range of 1.2 mm. At ×10 magnification, the area of normal
appearing neurons with nucleoli in the ventral horn was calcu-
lated using AxioVision (version 4.8, Carl Zeiss) and the
number of neurons in different size groups was determined.
Statistics
Analyses were performed using SPSS 16.0.2 software.
Log-rank was used to analyze survival and disease onset;
data from accelerating rotarod were analyzed by repeated
measures ANOVA. Univariate ANOVA was applied for
neuron counts. Student’s t-test or one-way ANOVA was
used for analyses of nerve conduction, disease duration,
mRNA expression levels and protein expression levels.
Chi-square test Pearson uncorrected was used to analyze the
frequencies of NMJ denervation. a was a priori set at 0.05.
Bonferroni’s correction was applied in cases of multiple com-
parisons.
Study approval
All animal experiments were approved by the local Ethical
Committee of the University of Leuven, Belgium (P020/
2010).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
The authors thank Dr Yao Tso-Pang from the Department of
Pharmacology and Cancer Biology, Duke University
(Durham, USA) for providing the Hdac6 KO mice.
Conflict of Interest statement. None declared.
FUNDING
This work was supported by grants from the University of
Leuven (KULeuven) (GOA/11/014); the InteruniversityAttrac-
tion Poles (IUAP) programP7/16 of theBelgian Federal Science
Policy Office; the European Community’s Health Seventh
Framework Programme (FP7/2007-2013 under grant agreement
259867); the Frick Foundation for ALS Research, ALS Therapy
Alliance; the Fund for Scientific Research, Flanders (FWO-F)
(G.0440.12N); the Ecole Polytechnique Fe´de´rale de Lausanne;
the EU Ideas program (ERC-2008-AdG-23118); L’Association
Franc¸aise contre les Myopathies (14471); the E von Behring
Chair for Neuromuscular and Neurodegenerative Disorders (to
W.R.); the Agency for Innovation by Science and Technology
in Flanders (IWT) (to I.T.); the Nestle´ Chair in EnergyMetabol-
ism (to J.A.); the Fund for Scientific Research Flanders
(FWO-F) (to P.V.D.); the Velux Stiftung; and the Swiss Nation-
al Science Foundation (31003A-124713).
REFERENCES
1. Dompierre, J.P., Godin, J.D., Charrin, B.C., Cordelieres, F.P., King, S.J.,
Humbert, S. and Saudou, F. (2007) Histone deacetylase 6 inhibition
compensates for the transport deficit in Huntington’s disease by increasing
tubulin acetylation. J. Neurosci., 27, 3571–3583.
2. Reed, N.A., Cai, D., Blasius, T.L., Jih, G.T., Meyhofer, E., Gaertig, J. and
Verhey, K.J. (2006) Microtubule acetylation promotes kinesin-1 binding
and transport. Curr. Biol., 16, 2166–2172.
3. d’Ydewalle, C., Krishnan, J., Chiheb, D.M., Van Damme, P., Irobi, J.,
Kozikowski, A.P., Berghe, P.V., Timmerman, V., Robberecht, W. and
Van Den Bosch, L. (2011) HDAC6 inhibitors reverse axonal loss in a
mouse model of mutant HSPB1-induced Charcot–Marie–Tooth disease.
Nat. Med., 17, 968–974.
4. Luthi-Carter, R., Taylor, D.M., Pallos, J., Lambert, E., Amore, A., Parker, A.,
Moffitt, H., Smith, D.L., Runne, H., Gokce, O. et al. (2010) SIRT2 inhibition
achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl Acad.
Sci. USA, 107, 7927–7932.
5. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn,
K.E., Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean,
P.J. et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated
toxicity in models of Parkinson’s disease. Science, 317, 516–519.
6. Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J.M., Steffan, J.S.,
Thompson, L.M. and Marsh, J.L. (2008) Inhibition of specific HDACs and
sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s
disease. Hum. Mol. Genet., 17, 3767–3775.
7. Narayan, N., Lee, I.H., Borenstein, R., Sun, J., Wong, R., Tong, G.,
Fergusson, M.M., Liu, J., Rovira, I.I., Cheng, H. et al. (2012) The
NAD-dependent deacetylase SIRT2 is required for programmed necrosis.
Nature, 492, 199–204.
8. Kawaguchi, Y.,Kovacs, J.J.,McLaurin,A.,Vance, J.M., Ito,A. andYao,T.P.
(2003) The deacetylase HDAC6 regulates aggresome formation and cell
viability in response to misfolded protein stress. Cell, 115, 727–738.
9. Iwata, A., Riley, B.E., Johnston, J.A. and Kopito, R.R. (2005) HDAC6
and microtubules are required for autophagic degradation of aggregated
huntingtin. J. Biol. Chem., 280, 40282–40292.
10. Boillee, S., Vande Velde, C. and Cleveland, D.W. (2006) ALS: a disease
of motor neurons and their nonneuronal neighbors. Neuron, 52, 39–59.
11. Ilieva, H., Polymenidou, M. and Cleveland, D.W. (2009) Non-cell
autonomous toxicity in neurodegenerative disorders: ALS and beyond.
J. Cell Biol., 187, 761–772.
12. Bilsland, L.G., Sahai, E., Kelly, G., Golding, M., Greensmith, L. and
Schiavo, G. (2010) Deficits in axonal transport precede ALS symptoms in
vivo. Proc. Natl Acad. Sci. USA, 107, 20523–20528.
13. Williamson, T.L. and Cleveland, D.W. (1999) Slowing of axonal transport
is a very early event in the toxicity of ALS-linked SOD1 mutants to motor
neurons. Nat. Neurosci., 2, 50–56.
14. Okamoto, K., Hirai, S., Shoji, M., Senoh, Y. and Yamazaki, T. (1990)
Axonal swellings in the corticospinal tracts in amyotrophic lateral
sclerosis. Acta Neuropathol., 80, 222–226.
15. Sasaki, S. and Maruyama, S. (1992) Increase in diameter of the axonal
initial segment is an early change in amyotrophic lateral sclerosis.
J. Neurol. Sci., 110, 114–120.
16. Beirowski, B., Gustin, J., Armour, S.M., Yamamoto, H., Viader, A.,
North, B.J., Michan, S., Baloh, R.H., Golden, J.P., Schmidt, R.E. et al.
(2011) Sir-two-homolog 2 (Sirt2) modulates peripheral myelination
through polarity protein Par-3/atypical protein kinase C (aPKC) signaling.
Proc. Natl Acad. Sci. USA, 108, E952–E961.
Human Molecular Genetics, 2013, Vol. 22, No. 9 1789
17. Gao, Y.S., Hubbert, C.C., Lu, J., Lee, Y.S., Lee, J.Y. and Yao, T.P. (2007)
Histone deacetylase 6 regulates growth factor-induced actin remodeling
and endocytosis. Mol. Cell. Biol., 27, 8637–8647.
18. Maxwell, M.M., Tomkinson, E.M., Nobles, J., Wizeman, J.W., Amore,
A.M., Quinti, L., Chopra, V., Hersch, S.M. and Kazantsev, A.G. (2011)
The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that
accumulates in the aging CNS. Hum. Mol. Genet., 20, 3986–3996.
19. Veldink, J.H., Bar, P.R., Joosten, E.A., Otten, M., Wokke, J.H. and van
den Berg, L.H. (2003) Sexual differences in onset of disease and response
to exercise in a transgenic model of ALS. Neuromuscul. Disord., 13, 737–
743.
20. Chevalier-Larsen, E. and Holzbaur, E.L. (2006) Axonal transport and
neurodegenerative disease. Biochim. Biophys. Acta, 1762, 1094–1108.
21. Lee, J.Y., Nagano, Y., Taylor, J.P., Lim, K.L. and Yao, T.P. (2010)
Disease-causing mutations in parkin impair mitochondrial ubiquitination,
aggregation, andHDAC6-dependentmitophagy. J. Cell Biol., 189, 671–679.
22. Pandey, U.B., Batlevi, Y., Baehrecke, E.H. and Taylor, J.P. (2007)
HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system
and neurodegeneration. Autophagy, 3, 643–645.
23. Pandey, U.B., Nie, Z., Batlevi, Y., McCray, B.A., Ritson, G.P., Nedelsky,
N.B., Schwartz, S.L., DiProspero, N.A., Knight, M.A., Schuldiner, O.
et al. (2007) HDAC6 rescues neurodegeneration and provides an essential
link between autophagy and the UPS. Nature, 447, 859–863.
24. Bobrowska, A., Paganetti, P., Matthias, P. and Bates, G.P. (2011) Hdac6
knock-out increases tubulin acetylation but does not modify disease
progression in the R6/2 mouse model of Huntington’s disease. PloS one,
6, e20696.
25. Li, W., Zhang, B., Tang, J., Cao, Q., Wu, Y., Wu, C., Guo, J., Ling, E.A.
and Liang, F. (2007) Sirtuin 2, a mammalian homolog of yeast silent
information regulator-2 longevity regulator, is an oligodendroglial protein
that decelerates cell differentiation through deacetylating alpha-tubulin.
J. Neurosci., 27, 2606–2616.
26. North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M. and Verdin, E. (2003)
The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin
deacetylase. Mol. Cell, 11, 437–444.
27. Bobrowska, A., Donmez, G., Weiss, A., Guarente, L. and Bates, G. (2012)
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol
biosynthesis or the progression of Huntington’s disease phenotypes in
vivo. PloS one, 7, e34805.
28. Southwood, C.M., Peppi, M., Dryden, S., Tainsky, M.A. and Gow, A.
(2007) Microtubule deacetylases, SirT2 and HDAC6, in the nervous
system. Neurochem. Res., 32, 187–195.
29. Lee, Y., Morrison, B.M., Li, Y., Lengacher, S., Farah, M.H., Hoffman,
P.N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.W. et al. (2012)
Oligodendroglia metabolically support axons and contribute to
neurodegeneration. Nature, 487, 443–448.
1790 Human Molecular Genetics, 2013, Vol. 22, No. 9
